LGVN - Longeveron completes Phase I/II Lomecel-B influenza vaccine study

Longeveron (LGVN) announces the completion of the company’s Phase I/II clinical study of the use of Lomecel-B to improve immune response to influenza vaccine in subjects with Aging Frailty.The company expects to announce top-line trial results in the third-quarter of 2021.In the Phase II trial, a total of 39 subjects were enrolled and treated, with 20 receiving placebo and 19 receiving Lomecel-B, with the primary objectives of assessing the safety, and efficacy of Lomecel-B to improve response to flu vaccine through measurement of serum antibodies.Lomecel-B has the potential to reduce inflammation associated with Aging Frailty, and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can balance the immune system and improve the function of B lymphocytes, the company said.Shares up more than 1% premarket.

For further details see:

Longeveron completes Phase I/II Lomecel-B influenza vaccine study